MDCalc

PREVAIL Model for Prostate Cancer Survival

Predicts overall survival in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.

This calculator has not been externally validated.

Treatment with enzalutamide planned
ng/mL
months
Neutrophil to lymphocyte ratio <2.5
Neutrophil number divided by lymphocyte number
LDH below upper limit of normal
Pain 0-1
On a scale of 0-10, 10 being the worst pain imaginable, highest pain rating in last 24 hrs
<10 bone metastases on bone scan
Alkaline phosphatase less than upper limit of normal
Pattern of spread

Result:

Please fill out required fields.
Advice
  • The study authors note limited direct clinical utility.
  • Use as supportive information rather than a sole determinant of care; combine with thorough clinical evaluation, specialist consultation, and sound judgment.
  • Results may be helpful for:
    • Goals-of-care discussions with patients and families.
    • Shaping clinical trial designs.
    • Stratifying patients for clinical trials.